Global Health & Biotech Archives | Page 44 of 287 | Be Korea-savvy

Archive by category Global Health & Biotech

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz US has entered into a settlement agreement with the class of end payer plaintiffs for USD 275 million Provision of USD 265 million taken to cover potential additional settlement costs with regard to the US generic drug industry antitrust litigation No impact on [...]

The Wistar Institute Receives Two Biomedical Research Grants from the V Foundation for Cancer Research

The Wistar Institute Receives Two Biomedical Research Grants from the V Foundation for Cancer Research

Grants Fund Projects Aimed at Improving Cancer Therapy PHILADELPHIA, PA, Dec. 16, 2024 (Korea Bizwire) – The Wistar Institute assistant professors Nan Zhang, Ph.D., and Noam Auslander Ph.D., have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V [...]

Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless).  AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for [...]

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

VANCOUVER, British Columbia, Dec. 16, 2024 (Korea Bizwire) – Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the expansion of its industry-leading offering. Cannabinol (CBN) is available as an EU-GMP certified API, D9-Tetrahydrocanabinol (THC) is in a solid crystalline form, undergoing enhanced stability optimization work and [...]

At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy

At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy

With its adoption of “zero-footprint” technology, ZEfiRO guarantees clinician and operators immediacy and usability in reading images wherever they are, with a positive impact on the management of diagnosis and treatment BERLIN and GENOA, Italy, Dec. 13, 2024 (Korea Bizwire) – EBIT s.r.l., the Esaote Group company that leads the Information Technology sector in the Healthcare [...]

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in England, marked [...]

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research

  ATHENS, Greece, Dec. 12, 2024 (Korea Bizwire) – FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements in food allergy and anaphylaxis research. The event featured impactful sessions, debates, workshops, and plenary discussions, highlighting new evidence and the importance of collaboration in tackling [...]

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company’s solid tumor portfolio Expansion into autoimmune and inflammatory diseases (AIID) and hematology oncology [...]

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Provides significant resources to build on diversified portfolio of established and rare disease medicines Egham, UK – 12 December 2024 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announces the completion of [...]

Io Therapeutics, Inc., Announces Presentation of Data from Studies of Its RAR Gamma Agonist Compound IRX5010 in Treatment of a Mouse Model of Triple Negative Breast Cancer, Demonstrating Combination Treatment Effects with an Anti-PDL-1 Monoclonal Antibody Checkpoint Inhibitor

Io Therapeutics, Inc., Announces Presentation of Data from Studies of Its RAR Gamma Agonist Compound IRX5010 in Treatment of a Mouse Model of Triple Negative Breast Cancer, Demonstrating Combination Treatment Effects with an Anti-PDL-1 Monoclonal Antibody Checkpoint Inhibitor

The combination treatment resulted in increased numbers of anti-cancer tumor-infiltrating T-cells; decreased numbers of anti-cancer response inhibiting tumor-infiltrating myeloid derived suppressor cells; and substantial 84% inhibition of tumor growth SPRING, Texas, Dec. 11 (Korea Bizwire) — Io Therapeutics, Inc., presented results from studies done in a mouse model of triple negative breast cancer with the [...]